RÉSUMÉ
The introduction of the drug-eluting (DES) stent to percutaneous coronary intervention (PCI) had a significant impact on patient management of coronary artery disease and has been called the "third revolution" in interventional cardiology after the first 2 revolutions of balloon angioplasty and bare-metal stents. The promise of adaptive remodeling, restoration of vasomotion, late luminal enlargement, and retained potential for future coronary artery bypass grafting at the site of previous PCI has been the driving force behind bioresorbable stent/scaffold (BRS) technology development. Moreover, because of the inherent risk of late and very late stent thrombosis, BRS potentially offers a solution and recent years have seen heightened interest, hype, and hope. In this current review, we are aiming to shed light on strength and weakness of various BRS including the future perspective. (AU)
La introducción del stent liberador de fármacos (DES) en la intervención coronaria percutánea (ICP) tuvo un impacto significativo en el tratamiento de los pacientes con enfermedad de las arterias coronarias y se ha denominado la "tercera revolución" en cardiología intervencionista después de las dos primeras revoluciones de la angioplastia con balón y stents de metal desnudo. La promesa de remodelación adaptativa, restauración de la vasomoción, agrandamiento luminal tardío y potencial retenido para futuros injertos de derivación de la arteria coronaria en el sitio de la PCI anterior ha sido la fuerza impulsora detrás del desarrollo de la tecnología de stent/armazón biorreabsorbible (BRS). Además, debido al riesgo inherente de trombosis del stent tardía y muy tardía, la BRS ofrece potencialmente una solución y en los últimos años se ha visto un mayor interés, entusiasmo y esperanza. En esta revisión actual, nuestro objetivo es arrojar luz sobre la fortaleza y la debilidad de varios BRS, incluida la perspectiva futura. (AU)
Sujet(s)
Humains , Angioplastie/tendances , Endoprothèses/tendances , Implant résorbable/tendances , Intervention coronarienne percutanée/tendancesRÉSUMÉ
Implant therapy after osteosarcoma surgery is a major clinical challenge currently, especially the requirements for mechanical properties, degradability of the implants, and their inhibition of residual tumor cells. Biodegradable magnesium (Mg) alloy as medical bone implant material has full advantages and huge potential development space. Wherein, Mg-lithium (Li) based alloy, as an ultra-light alloy, has good properties for implants under certain conditions, and both Mg and Li have inhibitory effects on tumor cells. Therefore, Mg-Li alloy is expected to be applied in bone implant materials for mechanical supporting and inhibiting tumor cells simultaneously. In this contribution, the Mg-xLi-Zinc (Zn) series alloys (x = 3 wt%, 6 wt%, 9 wt%) were prepared to study the influence of different elements and contents on the structure and properties of the alloy, and the biosafety of the alloy was also evaluated. Our data showed that the yield strength, tensile strength, and elongation of as-cast Mg-xLi-Zn alloy were higher than those of as-cast Mg-Zn alloy; Mg-xLi-Zn alloy can kill osteosarcoma cells (MG-63) in a concentration-dependent manner, wherein Mg-3Li-Zn alloy (x = 3 wt%) and Mg-6Li-Zn alloy (x = 6 wt%) promoted the proliferation of osteoblasts (MC3T3) at a certain concentration of Li. In summary, our study demonstrated that the Mg-6Li-Zn alloy could be potentially applied as a material of orthopedic implant for its excellent multi-functions.
Sujet(s)
Implant résorbable/tendances , Alliages/composition chimique , Composés du lithium/composition chimique , Composés du magnésium/composition chimique , Composés du zinc/composition chimique , Tumeurs osseuses/chirurgie , Adhérence cellulaire , Humains , Concentration en ions d'hydrogène , Test de matériaux , Ostéoblastes , Ostéosarcome/chirurgie , Facteurs tempsRÉSUMÉ
The metamorphosis of biodegradable polymers in biomedical applications is an auspicious myriad of indagation. The utmost challenge in clinical conditions includes trauma, organs failure, soft and hard tissues, infection, cancer and inflammation, congenital disorders which are still not medicated efficiently. To overcome this bone of contention, proliferation in the concatenation of biodegradable materials for clinical applications has emerged as a silver bullet owing to eco-friendly, nontoxicity, exorbitant mechanical properties, cost efficiency, and degradability. Several bioimplants are designed and fabricated in a way to reabsorb or degrade inside the body after performing the specific function rather than eliminating the bioimplants. The objective of this comprehensive is to unfurl the anecdote of emerging biological polymers derived implants including silk, lignin, soy, collagen, gelatin, chitosan, alginate, starch, etc. by explicating the selection, fabrication, properties, and applications. Into the bargain, emphasis on the significant characteristics of current discernment and purview of nanotechnology integrated biopolymeric implants has also been expounded. This robust contrivance shed light on recent inclinations and evolution in tissue regeneration and targeting organs followed by precedency and fly in the ointment concerning biodegradable implants evolved by employing fringe benefits provided by 3D printing technology for building tissues or organs construct for implantation.
Sujet(s)
Implant résorbable/tendances , Matériaux biocompatibles/composition chimique , Animaux , Chitosane/composition chimique , Collagène/métabolisme , Gélatine/composition chimique , Humains , Nanotechnologie/méthodes , Polymères/composition chimique , Impression tridimensionnelle/tendances , Ingénierie tissulaire/méthodes , Structures d'échafaudage tissulaires/composition chimiqueRÉSUMÉ
Compared with non-degradable materials, biodegradable biomaterials play an increasingly important role in the repairing of severe bone defects, and have attracted extensive attention from researchers. In the treatment of bone defects, scaffolds made of biodegradable materials can provide a crawling bridge for new bone tissue in the gap and a platform for cells and growth factors to play a physiological role, which will eventually be degraded and absorbed in the body and be replaced by the new bone tissue. Traditional biodegradable materials include polymers, ceramics and metals, which have been used in bone defect repairing for many years. Although these materials have more or fewer shortcomings, they are still the cornerstone of our development of a new generation of degradable materials. With the rapid development of modern science and technology, in the twenty-first century, more and more kinds of new biodegradable materials emerge in endlessly, such as new intelligent micro-nano materials and cell-based products. At the same time, there are many new fabrication technologies of improving biodegradable materials, such as modular fabrication, 3D and 4D printing, interface reinforcement and nanotechnology. This review will introduce various kinds of biodegradable materials commonly used in bone defect repairing, especially the newly emerging materials and their fabrication technology in recent years, and look forward to the future research direction, hoping to provide researchers in the field with some inspiration and reference.
Sujet(s)
Implant résorbable/normes , Substituts osseux/normes , Implant résorbable/tendances , Substituts osseux/usage thérapeutique , Humains , Procédures orthopédiques/instrumentation , Procédures orthopédiques/méthodes , Ingénierie tissulaire/instrumentation , Ingénierie tissulaire/méthodesRÉSUMÉ
As the number of patients afflicted by chronic limb-threatening ischemia (CLTI) continues to grow, new solutions are necessary to provide effective, durable treatment options that will lead to improved outcomes. The diagnosis of CLTI remains mostly clinical, and endovascular revascularization remains mostly balloon-based. Multiple innovative techniques and technologies are in development or in early usage that may provide new solutions. This review categorizes areas of advancement, highlights recent developments in the management of CLTI and looks forward to novel devices that are currently under investigation.
Sujet(s)
Procédures endovasculaires/tendances , Ischémie/thérapie , Maladie artérielle périphérique/thérapie , Implant résorbable/tendances , Amputation chirurgicale/tendances , Maladie chronique , Matériaux revêtus, biocompatibles , Diffusion des innovations , Endoprothèses à élution de substances/tendances , Procédures endovasculaires/effets indésirables , Procédures endovasculaires/instrumentation , Humains , Ischémie/imagerie diagnostique , Ischémie/physiopathologie , Sauvetage de membre/tendances , Maladie artérielle périphérique/imagerie diagnostique , Maladie artérielle périphérique/physiopathologie , Conception de prothèse/tendances , Facteurs de risque , Résultat thérapeutique , Dispositifs d'accès vasculaires/tendancesRÉSUMÉ
BACKGROUND: Females are underrepresented in clinical trials evaluating new stent technologies whilst results may differ between the sexes. Females are known to have smaller, more tortuous coronary arteries and have generally more comorbidities. On the other hand, they may have smaller plaque burden. This subgroup-analysis sought to assess sex-specific outcomes after Absorb bioresorbable vascular scaffold (BVS) or XIENCE everolimus-eluting stent (EES) implantation. METHODS: The AIDA trial was an investigator-initiated, non-inferiority, all-comers trial, in which 1845 patients were randomly assigned to either Absorb BVS or XIENCE EES. Baseline clinical, angiography and procedural variables, as well as 2-year clinical outcomes were analyzed by sex and device modality. RESULTS: Of the 1845 randomized patients, 475 (25.7%) were females. The 2-year rates of target vessel failure (TVF) with Absorb BVS versus XIENCE EES in females were 6.4% versus 10.6% (HR 0.59; 95% CI: 0.31-1.11; pâ¯=â¯0.10) and in males 12.7% versus 9.7% (HR 1.34; 95% CI: 0.98-1.85; pâ¯=â¯0.07). Males treated with Absorb BVS were at higher risk for TVF compared to females treated with Absorb BVS (HR 2.06; 95% CI 1.21-3.53; pâ¯=â¯0.007). Definite/probable device thrombosis occurred in females with Absorb BVS versus XIENCE EES in 1.6% versus 1.4% (HR 1.15; 95% CI: 0.26-5.12; pâ¯=â¯0.86) and in males 3.9% versus 0.7% (HR 5.55; 95% CI: 2.11-14.35; pâ¯<â¯0.001). A statistical significant interaction between sex and device was present for TVF (pâ¯=â¯0.02), but was not seen for definite/probable device thrombosis (pâ¯=â¯0.08). CONCLUSIONS: In this subgroup analysis, Absorb BVS used in routine practice tends to result in better clinical outcomes in females compared to males.
Sujet(s)
Implant résorbable/tendances , Bioprothèse/tendances , Maladie des artères coronaires/imagerie diagnostique , Maladie des artères coronaires/chirurgie , Caractères sexuels , Structures d'échafaudage tissulaires/tendances , Sujet âgé , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Méthode en simple aveugle , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
STUDY DESIGN: A controlled, interventional animal study. OBJECTIVE: Spinal implant infection (SII) is a devastating complication. The objective of this study was to evaluate the efficacy of a novel implant coating that has both a passive antibiotic elution and an active-release mechanism triggered in the presence of bacteria, using an in vivo mouse model of SII. SUMMARY OF BACKGROUND DATA: Current methods to minimize the frequency of SII include local antibiotic therapy (vancomycin powder), betadine irrigation, silver nanoparticles, and passive release from antibiotic-loaded poly(methyl methacrylate) cement beads, all of which have notable weaknesses. A novel implant coating has been developed to address some of these limitations but has not been tested in the environment of a SII. METHODS: A biodegradable coating using branched poly(ethylene glycol)-poly(propylene sulfide) (PEG-PPS) polymer was designed to deliver antibiotics. The in vivo performance of this coating was tested in the delivery of either vancomycin or tigecycline in a previously established mouse model of SII. Noninvasive bioluminescence imaging was used to quantify the bacterial burden, and implant sonication was used to determine bacterial colony-forming units (CFUs) from the implant and surrounding bone and soft tissue. RESULTS: The PEG-PPS-vancomycin coating significantly lowered the infection burden from postoperative day 3 onwards (Pâ<â0.05), whereas PEG-PPS-tigecycline only decreased the infection on postoperative day 5 to 10 (Pâ<â0.05). CFUs were lower on PEG-PPS-vancomycin pins than PEG-PPS-tigecycline and PEG-PPS pins alone on both the implants (2.4â×â10, 8.5â×â10, and 1.0â×â10 CFUs, respectively) and surrounding bone and soft tissue (1.3â×â10, 4.8â×â10, and 5.4â×â10 CFUs, respectively) (Pâ<â0.05). CONCLUSION: The biodegradable PEG-PPS coating demonstrates promise in decreasing bacterial burden and preventing SII. The vancomycin coating outperformed the tigecycline coating in this model compared to prior work in arthroplasty models, highlighting the uniqueness of the paraspinal infection microenvironment. LEVEL OF EVIDENCE: N/A.
Sujet(s)
Implant résorbable , Antibactériens/administration et posologie , Polyéthylène glycols/administration et posologie , Prothèses et implants/effets indésirables , Infections dues aux prothèses/prévention et contrôle , Infections à staphylocoques/prévention et contrôle , Implant résorbable/tendances , Animaux , Implant pharmaceutique , Humains , Souris , Souris de lignée C57BL , Complications postopératoires/traitement médicamenteux , Complications postopératoires/étiologie , Infections dues aux prothèses/étiologie , Infections à staphylocoques/étiologie , Vancomycine/administration et posologieRÉSUMÉ
PURPOSE OF REVIEW: The purpose of this review is to explore the evolution of the coronary stent, from the advent of bare-metal stents, to the newest adopted technology of bioresorbable vascular scaffolds (BVS) used in bioresorbable stents. To date, there have been conflicting data regarding the safety and efficacy of BVS stents, especially when compared to current-generation drug-eluting stents (DES). This review will cover the data that exist regarding current BVS stents, as well as the active clinical trials for future iterations of BVS. RECENT FINDINGS: The ABSORB BVS, the most widely circulated stent of its class, was promised to decrease rates of stent thrombosis and target vessel revascularization. Several randomized control trials, however, found the opposite to be true, with the ABSORB BVS demonstrating higher rates of thrombosis, target vessel revascularization, and even target lesion myocardial infarctions when compared to current-generation DES. These data caused the product to be pulled from all markets, leaving the field with uncertainty as to the role of BVS in coronary interventions. Coronary stents have evolved significantly from 1977, when they were first introduced. The original bare-metal stent was later fitted with a drug-eluting polymer, to prevent restenosis and thrombosis over time. Subsequent iterations of the stent attempted to further mitigate that risk by replacing the durable polymer to one that is bioresorbable. The final step in this progression was to create a stent that was fully bioresorbable, which Abbott did with the creation of their ABSORB BVS stent. The product, however, was found to perform poorly when compared to current-generation drug-eluting stents, with several trials showing high rates of stent thrombosis (ST), late stent thrombosis (LST), target-lesion myocardial infarction, and target vessel revascularization. Observational studies of BVS stents have proposed several mechanisms for their thrombogenicity, including higher stent-strut profiles leading to turbulent flow, low radial strength leading to strut disruption, and a higher propensity for neoatherosclerosis. Given the failure of the first-generation BVS stent, but the lingering desire for fully bioresorbable scaffolds, various manufacturers have proposed their solutions with new stents. Until data from their clinical trials emerge, it remains unclear whether fully bioresorbable stents will play any role in coronary interventions.
Sujet(s)
Implant résorbable/tendances , Endoprothèses à élution de substances/tendances , Infarctus du myocarde/étiologie , Intervention coronarienne percutanée/méthodes , Thrombose/étiologie , Humains , Copolymère d'acide poly(lactique-co-glycolique)/composition chimique , Conception de prothèse/tendances , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Recent studies showed bioresorbable scaffold (BRS) increased risks of late target lesion failure (TLF) and thrombosis. XINSORB scaffold is a poly-L-lactic acid based BRS. METHODS: The study included randomization and registry parts. Eligible patients with one or two de novo lesions were randomly 1:1 assigned to XINSORB scaffold and sirolimus-eluting stent (SES) in randomization part. These patients were clinically and angiographically assessed. In registry part, patients were treated with XINSORB scaffold only and were clinically assessed. The primary endpoint was in-segment late luminal loss (LLL) at 12-month in randomization part. The secondary endpoint was 12-month TLF in all XINSORB-treated patients. RESULTS: Total 395 and 798 patients were enrolled in randomization and registry part, respectively. Device success was 98.0% (1069/1091) in all XINSORB-treated and 100% (221/221) in SES-treated lesions. The primary endpoint of in-segment LLL at 12-month was 0.19⯱â¯0.32â¯mm in XINSORB and 0.31⯱â¯0.41â¯mm in SES (Pâ¯=â¯0.003), which met the noninferior margin of 0.195â¯mm (95% CI: -0.20, -0.04, Pâ¯âªâ¯0.0001). No difference was found in TLF between two devices. In all XINSORB-treated patients, 12-month TLF was 0.8% (8/998), which also met the noninferior margin of 9.0% (95% CI: 0.3%, 1.4%, Pâ¯âªâ¯0.0001). Only one device thrombosis was recorded in all XINSORB-treated patients while none in SES. CONCLUSIONS: In the multicenter clinical trial, XINSORB BRS was noninferior to sirolimus-eluting stent for the primary endpoint of in-segment LLL at 12-month in patients with simple and moderate complex de novo coronary lesions. TLF at 12-month was low and comparable.
Sujet(s)
Implant résorbable/tendances , Alliages de chrome , Coronarographie/tendances , Maladie des artères coronaires/imagerie diagnostique , Endoprothèses à élution de substances/tendances , Sirolimus/administration et posologie , Adolescent , Adulte , Sujet âgé , Coronarographie/méthodes , Maladie des artères coronaires/chirurgie , Femelle , Études de suivi , Humains , Immunosuppresseurs/administration et posologie , Mâle , Adulte d'âge moyen , Intervention coronarienne percutanée/instrumentation , Intervention coronarienne percutanée/tendances , Études prospectives , Endoprothèses/tendances , Facteurs temps , Résultat thérapeutique , Jeune adulteRÉSUMÉ
BACKGROUND: Drug eluting stents with biodegradable polymers have been developed to address the risk of very late adverse events. Long-term comparison data between the biodegradable polymer-coated biolimus-eluting stent (BES; Nobori®) and the second-generation durable polymer-coated everolimus-eluting stent (EES; XIENCE V® or XIENCE PRIME® or PROMUS™) in diabetic patients are scarce. METHODS: The COMPARE II trial was an investigator-initiated, multicenter, open-label, randomized, all-comers trial which assigned patients undergoing percutaneous coronary intervention (PCI) in a 2:1 fashion to either BES or EES. We analyzed the safety and efficacy outcomes in diabetic patients at 5â¯year follow-up. The primary pre-specified composite endpoint major adverse cardiac event (MACE) was defined as cardiac death, non-fatal target-vessel myocardial infarction (TV-MI), or clinically indicated target vessel revascularization (CD-TVR). RESULTS: Out of 2707 study patients, 588 were diabetics (21.7%) of whom 391 were treated with BES and 197 with EES. At 5â¯years follow-up, MACE occurred in 87 patients (22.2%) in the BES group and in 34 patients (17.2%) in the EES group (pâ¯=â¯.34). Other safety and efficacy endpoints did not differ between stent groups. CONCLUSIONS: At 5â¯years follow-up, no differences in terms of MACE as well as all analyzed safety and efficacy measures, including stent thrombosis, between the biodegradable polymer-coated BES and the durable polymer-coated EES in diabetic patients were observed.
Sujet(s)
Implant résorbable , Diabète/thérapie , Endoprothèses à élution de substances , Évérolimus/administration et posologie , Intervention coronarienne percutanée/méthodes , Sirolimus/analogues et dérivés , Implant résorbable/tendances , Sujet âgé , Sujet âgé de 80 ans ou plus , Diabète/diagnostic , Diabète/épidémiologie , Endoprothèses à élution de substances/tendances , Femelle , Études de suivi , Humains , Immunosuppresseurs/administration et posologie , Mâle , Adulte d'âge moyen , Intervention coronarienne percutanée/instrumentation , Intervention coronarienne percutanée/tendances , Polymères , Sirolimus/administration et posologie , Facteurs tempsRÉSUMÉ
BACKGROUND: Large prospective studies on the use of bioresorbable vascular scaffolds (BVS) for diffuse coronary artery disease are lacking. IT DISAPPEARS is a large multicentre prospective registry investigating the short and long-term outcomes of everolimus-eluting BVS in patients with long coronary lesions and/or multivessel coronary artery disease (ClinicalTrials.gov: NCT02004730). We hereby report the 2-year outcomes of the registry. METHODS: We enrolled 1002 patients with complex lesions undergoing implantation of 2040 BVS with a prespecified technique including predilation, correct sizing, and postdilation with non-compliant balloons. The primary endpoint was the rate of device-oriented composite endpoint (DOCE), consisting of cardiac death, target vessel-related myocardial infarction (MI), and ischaemia-driven target lesion revascularization (TLR). Secondary endpoints included: 1) patient-oriented composite endpoint (POCE), consisting of all-cause mortality, all infarctions and all revascularisations; 2) definite/probable scaffold thrombosis. RESULTS: Clinical presentation was an acute coronary syndrome in 59.8% of patients. Total BVS length implanted was 47⯱â¯22â¯mm. Postdilation of all scaffolds per patient was performed in 96.8%, while optimal implantation as per study guidelines was applied in 71.4%. Through 2-year follow-up, DOCE occurred in 9.5% of patients (cardiac death 0.6%, target vessel-related MI 5.3%, TLR 6.6%). The rate of POCE was 16.6% and of scaffold thrombosis 1.1%. Female gender, total length of coronary lesions, treatment of bifurcation lesions and use of 2.5â¯mm scaffolds were independent predictors of DOCE. CONCLUSIONS: The 2-year results of IT-DISAPPEARS show that BVS may yield acceptable clinical outcomes in patients with complex coronary lesions when the implantation technique is appropriate.
Sujet(s)
Implant résorbable/tendances , Syndrome coronarien aigu/épidémiologie , Syndrome coronarien aigu/thérapie , Endoprothèses à élution de substances/tendances , Évérolimus/administration et posologie , Enregistrements , Sujet âgé , Femelle , Études de suivi , Humains , Italie/épidémiologie , Mâle , Adulte d'âge moyen , Études prospectives , Facteurs temps , Structures d'échafaudage tissulaires/tendances , Résultat thérapeutiqueRÉSUMÉ
Ureteral stents are an indispensable tool in contemporary urologic patient care. They have become first-line devices for maintenance of ureteral patency postoperatively and in cases of ureteral narrowing. Despite their widespread use, these implants are associated with multiple complications including stent colic, infection, and encrustation. There is no ideal ureteric stent currently available. The aim of most recent stent innovation has been to make steps toward properties of an ideal stent. This article reviews recent technological advances in stent design and how they have attempted to tackle issues that urologists and patients face with ureteral stents.
Sujet(s)
Implant résorbable , Conception de prothèse , Endoprothèses , Uretère/chirurgie , Implant résorbable/tendances , Matériaux biocompatibles , Cathéters à demeure , Matériaux revêtus, biocompatibles , Ablation de dispositif , Humains , Inventions , Métaux , Polymères , Conception de prothèse/tendances , Endoprothèses/tendancesRÉSUMÉ
BACKGROUND: The extensile lateral approach (ELA) has been widely used to treat displaced intra-articular calcaneal fractures (DIACFs) and remains the gold standard procedure. Orthopedic surgeons are extremely concerned of the high rate of wound complications. This study intended to report a new surgical technique of the lateral wall osteotomy combined with an embedded biodegradable implant for treating DIACFs and assess clinical and radiological results. METHODS: From May 2013 to December 2015, a total of 17 patients with 19 calcaneal fractures underwent surgical treatment using our new technique. Radiographic images, computed tomography (CT) scans, and magnetic resonance (MR) images of the operative limb were obtained to assess fracture healing and biodegradable implant degradation. American Orthopaedic Foot and Ankle Society (AOFAS) ankle/hindfoot score at the last follow-up was obtained to assess functional result for all cases. Böhler's and Gissane's angles, width, and height of the injured calcaneus were analyzed using preoperative and last follow-up radiographic images. RESULTS: All radiological parameters were significantly improved at the last follow-up, with an increase of 15.58°, 8.38°, and 7.65 mm in Böhler's angle, Gissane's angle, and calcaneal height, respectively, and a decrease of 2.51 mm in calcaneal width (p < 0.05). Mean AOFAS score at the last follow-up was 84.37 ± 9.98, with 9, 6, and 4 feet, having excellent, good, and fair rates, respectively. None had nonunion, delayed union, or malunion after a mean follow-up of 34.69 ± 5.22 months. One superficial infection occurred 6 days post-surgery. CONCLUSIONS: Osteotomy of the lateral wall of the calcaneus allows tension-free suturing and avoids damage to penetrating branches of the lateral calcaneal artery (LCA). Biodegradable implants are easy to reshape and do not require surgical removal. However, they should be limited to Sander's type II and III fractures only. LEVEL OF EVIDENCE: Level IV, case series without controls.
Sujet(s)
Implant résorbable , Calcanéus/chirurgie , Ostéosynthèse interne , Fractures articulaires/chirurgie , Ostéotomie/méthodes , Implant résorbable/tendances , Adulte , Calcanéus/imagerie diagnostique , Calcanéus/traumatismes , Femelle , Études de suivi , Ostéosynthèse interne/tendances , Humains , Fractures articulaires/imagerie diagnostique , Mâle , Adulte d'âge moyenRÉSUMÉ
BACKGROUND: This study aimed to evaluate real-world clinical outcome of patients needing short dual antiplatelet therapy (S-DAPT) following PCI with Ultimaster® thin-strut, biodegradable polymer sirolimus-eluting stent (BP-SES), which was supposed to induce faster stent endothelialization and reduce device thrombogenicity. METHODS: In this sub-group analysis of patients enrolled in the ULISSE registry, two groups were identified: 1) patients discharged with S-DAPT (≤3-month) due to high bleeding risk or need for urgent major non-cardiac surgery and 2) patients discharged with recommended DAPT (R-DAPT) duration (≥6-month). The primary ischemic-safety and bleeding-safety endpoints were TLF (composite of cardiac-death, target vessel MI, and clinically driven target lesion revascularization), and BARC major bleedings (≥type-3a) at 1-year follow-up. To account for events occurring before DAPT discontinuation we performed 3-month landmark analysis. RESULTS: 82 patients (5%) were discharged with ≤3-month DAPT (57⯱â¯27â¯days), and 1558 patients (94%) were discharged with ≥6-month DAPT (318⯱â¯75â¯days). No significant differences between S-DAPT and R-DAPT group were observed in TLF at 1-year (7.9% vs. 4.6%). The rate of BARC major bleeding resulted significantly higher in S-DAPT group (3.9% vs. 0.3%; pâ¯=â¯0.001), with the majority of bleeding events occurring within 3â¯months. The landmark analysis showed no significant differences in BARC major bleedings between groups (1.4% vs. 0.3%; pâ¯=â¯0.142). CONCLUSIONS: As compared to those treated with R-DAPT (≥6-month), patients needing -S-DAPT (≤3-month) after PCI with Ultimaster® BP-SES had similar rates of 1-year TLF and BARC major bleedings following early DAPT discontinuation.
Sujet(s)
Implant résorbable/tendances , Syndrome coronarien aigu/thérapie , Endoprothèses à élution de substances/tendances , Antiagrégants plaquettaires/administration et posologie , Enregistrements , Sirolimus/administration et posologie , Syndrome coronarien aigu/imagerie diagnostique , Syndrome coronarien aigu/épidémiologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Études de suivi , Humains , Immunosuppresseurs/administration et posologie , Italie/épidémiologie , Adulte d'âge moyen , Polymères , Études rétrospectives , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Coronary drug-eluting stent development has introduced new metal alloys, changes in stent architecture, and bioresorbable polymers. Whether these advancements improve long-term clinical safety and efficacy has been inconsistent in prior studies. OBJECTIVES: The authors sought to compare late-term clinical outcomes among patients treated with an ultrathin strut (60 µm) bioresorbable polymer sirolimus-eluting stent (BP SES) and a thin strut (81 µm) durable polymer everolimus-eluting stent (DP EES) in a large randomized trial. METHODS: BIOFLOW V (Biotronik Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment of Subjects with Up to Three De Novo or Restenotic Coronary Artery Lesions V) was an international randomized trial comparing coronary revascularization with BP SES and DP EES regarding the primary endpoint of 12-month target lesion failure (TLF). Analysis of pre-specified 2-year clinical outcomes was performed. RESULTS: Among 1,334 patients randomized to treatment with BP SES (n = 884) or DP EES (n = 450), the 2-year TLF rate was 7.5% for BP SES and 11.9% for DP EES (-4.33% treatment difference; 95% confidence interval: -8.16% to -0.91%; p = 0.015), driven by differences in target vessel myocardial infarction (MI) (5.3% vs. 9.5%; p = 0.01) and ischemia-driven target lesion revascularization (2.6% vs. 4.9%; p = 0.04). Rates of cardiac death or MI were 7.0% versus 10.4% for BP SES and DP EES, respectively (p = 0.047). Late/very late definite stent thrombosis was statistically lower for BP SES compared with DP EES (0.1% vs. 1.0%; p = 0.045). CONCLUSIONS: In a large randomized trial, significant differences in both TLF and target vessel-related MI persisted through 2 years, favoring treatment with BP SES over DP EES. Significantly lower cumulative target lesion revascularization and late/very late stent thrombosis were also observed with BP SES. (Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions [BIOFLOW-V]; NCT02389946).
Sujet(s)
Implant résorbable , Maladie des artères coronaires/thérapie , Endoprothèses à élution de substances , Évérolimus/administration et posologie , Polymères/administration et posologie , Sirolimus/administration et posologie , Implant résorbable/tendances , Sujet âgé , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/physiopathologie , Endoprothèses à élution de substances/tendances , Femelle , Études de suivi , Humains , Immunosuppresseurs/administration et posologie , Mâle , Adulte d'âge moyen , Études prospectives , Méthode en simple aveugleRÉSUMÉ
OBJECTIVES: The aim of this study was to evaluate the impact of a consistent and dedicated implantation strategy on long-term outcomes after implantation of bioresorbable vascular scaffold (BVS) in a real-world cohort of patients with a high prevalence of complex lesions. BACKGROUND: Bioresorbable vascular scaffolds may result in a reduced incidence of late and very-late scaffold thrombosis (ScT) after the complete reabsorption of the scaffold, but this hypothesis is hampered by data from RCTs that showed a higher than expected incidence of late events. However, these studies did not adopt a dedicated implantation technique, that proved to be fundamental in reducing the incidence of adverse events. METHODS: 573 consecutive patients (912 lesions) treated with bioresorbable scaffolds between May 2012 and December 2014 were enrolled in 3 high-volume centers that used a dedicated implantation strategy from the beginning. Primary endpoints were target-lesion failure (TLF) and definite and probable ScT. Secondary endpoints included myocardial infarction, target-lesion and target-vessel revascularization. RESULTS: The registry enrolled a high complexity subset of lesions (69.4% of type B2 or C lesions; 10.3% of severe calcific lesions; 26.1% of bifurcations). Predilatation was performed in almost all cases (99.2%); intracoronary imaging was liberally adopted (37.3%). Mean scaffold length was 42.9⯱â¯27.4â¯mm per patient, and post-dilation with a 1:1 high-pressure (22⯱â¯3.5â¯atm) balloon was performed in 99.9% of lesions. Median follow-up (available for 98.6% of patients) was 981â¯days (IQR 802-1133). Overall incidence of ScT was reassuringly low: three thrombotic events occurred during the first year (0.5%), while only one event ensued in the second year of follow-up, and ScT rate remained stable thereafter up to the fourth year (0.7%). Cumulative TLF rates at 1, 2, 3 and 4â¯years were 3.0%, 6.0%, 7.8% and 12.2%. CONCLUSIONS: These long-term results from a complex "real-world" population appear to be reassuring as regards to the incidence of ScT and TLF when BVS are implanted by experienced operators with a dedicated implantation technique.
Sujet(s)
Implant résorbable/tendances , Implantation de prothèses vasculaires/tendances , Prothèse vasculaire/tendances , Maladie des artères coronaires/chirurgie , Intervention coronarienne percutanée/tendances , Enregistrements , Implantation de prothèses vasculaires/méthodes , Maladie des artères coronaires/imagerie diagnostique , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Intervention coronarienne percutanée/instrumentation , Intervention coronarienne percutanée/méthodes , Études prospectives , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Little data are available on the long-term outcomes of bioresorbable scaffold (BRS) in the setting of ST-segment elevation myocardial infarction (STEMI). The aim of this study is to investigate three-years outcomes and predictors of BRS failure in patients presenting with STEMI. METHODS AND RESULTS: Two prospective, single-arm registries were pooled. Incidence and predictors of clinical outcome were assessed with Kaplan-Meier and Cox regression analyses. From May-2012 to January-2015, 183 STEMI patients (58⯱â¯13â¯years, 77% males, 29% diabetics) who received a total of 256 BRS (1.4⯱â¯0.8 per patient) were included. 248 patients (65⯱â¯11â¯years, 74% males, 27% diabetics) treated for stable coronary artery disease (SCAD) served as control. 3-years follow-up was available in 386 (90%) patients. Device-oriented composite endpoint and scaffold thrombosis (ScT) rates were similar in the two groups (STEMI: 11.5% vs SCAD: 12.9%, Pâ¯=â¯0.84; STEMI: 3.6% vs SCAD: 3.3%, Pâ¯=â¯0.90). While early ScT was more frequent in SCAD patients, late/very late ScT was a feature of STEMI. While in STEMI patients the incidence of ScT was higher in vessels with RVDâ¯>â¯3.5â¯mm, a RVDâ¯<â¯2.5â¯mm was a predictor of events in stable patients. Similarly, BRS undersizing predicted events in STEMI patients, while oversizing was a predictor in stable ones. Finally, the incidence of ScT was reduced in both STEMI and stable patients (from 6.3% to 0% and from 5.80% to 0.9%) when an optimized implantation technique was used. CONCLUSIONS: The incidence of events for three years follow-up was similar in STEMI and SCAD patients, although different timing and features underlie ScT in the two groups.
Sujet(s)
Implant résorbable/effets indésirables , Matériaux biocompatibles/effets indésirables , Défaillance de prothèse/effets indésirables , Infarctus du myocarde avec sus-décalage du segment ST/chirurgie , Structures d'échafaudage tissulaires/effets indésirables , Implant résorbable/tendances , Sujet âgé , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Valeur prédictive des tests , Défaillance de prothèse/tendances , Enregistrements , Infarctus du myocarde avec sus-décalage du segment ST/imagerie diagnostique , Facteurs tempsRÉSUMÉ
OBJECTIVES: The objective of this study was to investigate mid-term clinical outcomes of patients treated with 'full-plastic jacket' (FPJ) everolimus-eluting Absorb bioresorbable vascular scaffold (BRS) implantation. BACKGROUND: FPJ with BRS may represent an interesting option for patient with diffuse coronary artery disease (CAD), but data on the clinical impact of FPJ using the Absorb BRS are scant. METHODS: FPJ was defined as the implantation of >56â¯mm of overlapping BRS in at least one vessel. We compared outcomes of patients receiving Absorb FPJ vs. non-FPJ within the multicenter prospective RAI Registry. RESULTS: Out of 1505 consecutive patients enrolled in the RAI registry, 1384 were eligible for this analysis. Of these, 143 (10.3%) were treated with BRS FPJ. At a median follow-up of 649â¯days, no differences were observed between FPJ and non-FPJ groups in terms of the device-oriented composite endpoint (DoCE) (5.6% vs. 4.4%, pâ¯=â¯0.675) or the patient-related composite endpoint (PoCE) (20.9% vs. 15.9%, pâ¯=â¯0.149). Patients receiving FPJ had higher rates of target vessel repeat revascularization (TVR) (11.2% vs. 6.3%, pâ¯=â¯0.042). In the FPJ group, there was no cardiac death and only one (very late) stent thrombosis (ST) (0.7%). CONCLUSIONS: Mid-term outcomes of a FPJ PCI strategy in the setting of diffuse CAD did not show a significant increase in composite device- and patient-related events, with rates of cardiac death and ST comparable to non-FPJ Absorb BRS implantation. However, these findings are hypothesis generating and requiring further validation.
Sujet(s)
Implant résorbable , Prothèse vasculaire/tendances , Maladie des artères coronaires/thérapie , Endoprothèses à élution de substances/tendances , Évérolimus/administration et posologie , Enregistrements , Implant résorbable/tendances , Sujet âgé , Maladie des artères coronaires/imagerie diagnostique , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Études prospectives , Structures d'échafaudage tissulaires/tendances , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Acute thrombosis is a crucial cause of bioresorbable vascular graft (BVG) failure. Bone marrow-derived mononuclear cell (BM-MNC)-seeded BVGs demonstrated high graft patency, however, the effect of seeded BM-MNCs against thrombosis remains to be elucidated. Thus, we evaluated an antithrombotic effect of BM-MNC-seeding and utilized platelet-depletion mouse models to evaluate the contribution of platelets to acute thrombosis of BVGs. METHODS AND RESULTS: BVGs were composed of poly(glycolic acid) mesh sealed with poly(l-lactideco-ε-caprolactone). BM-MNC-seeded BVGs and unseeded BVGs were implanted to wild type C57BL/6 mice (nâ¯=â¯10/group) as inferior vena cava interposition conduits. To evaluate platelet effect on acute thrombosis, c-Mpl-/- mice and Pf4-Cre+; iDTR mice with decreased platelet number were also implanted with unseeded BVGs (nâ¯=â¯10/group). BVG patency was evaluated at 2, 4, and 8â¯weeks by ultrasound. BM-MNC-seeded BVGs demonstrated a significantly higher patency rate than unseeded BVGs during the acute phase (2-week, 90% vs 30%, pâ¯=â¯.020), and patency rates of these grafts were sustained until week 8. Similar to BM-MNC-seeded BVGs, C-Mpl-/- and Pf4-Cre+; iDTR mice also showed favorable graft patency (2-week, 90% and 80%, respectively) during the acute phase. However, the patency rate of Pf4-Cre+; iDTR mice decreased gradually after DTR treatment as platelet number recovered to baseline. An in vitro study revealed BM-MNC-seeding significantly inhibited platelet adhesion to BVGs compared to unseeded BVGs, (1.75⯱â¯0.45 vs 8.69⯱â¯0.68â¯×â¯103â¯platelets/mm2, pâ¯<â¯.001). CONCLUSIONS: BM-MNC-seeding and the reduction in platelet number prevented BVG thrombosis and improved BVG patency, and those results might be caused by inhibiting platelet adhesion to the BVG.
Sujet(s)
Implant résorbable , Prothèse vasculaire , Transplantation de moelle osseuse/méthodes , Adhésivité plaquettaire/physiologie , Thrombose/prévention et contrôle , Degré de perméabilité vasculaire/physiologie , Implant résorbable/tendances , Animaux , Prothèse vasculaire/tendances , Cellules de la moelle osseuse/physiologie , Transplantation de moelle osseuse/tendances , Cellules cultivées , Souris , Souris de lignée C57BL , Souris transgéniques , Polymères/administration et posologie , Thrombose/imagerie diagnostiqueRÉSUMÉ
Oesophageal stents are widely used for palliating dysphagia from malignant obstruction. They are also used with increasing frequency in the treatment of oesophageal perforation, as well as benign strictures from a variety of causes. Improved oncological treatments have led to prolonged survival of patients treated with palliative intent; as a consequence, stents need to function and last longer in order to avoid repeat procedures. There is also increasing need for meticulous procedure planning, careful selection of the device most appropriate for the individual patient and planned follow-up. Furthermore, as more patients are cured, there will be more issues with resultant long-term side-effects, such as recalcitrant strictures due to radiotherapy or anastomotic scarring, which will have to be addressed. Stent design needs to keep up with the progress of cancer treatment, in order to offer patients the best possible long-term result. This review article attempts to illustrate the changing realities in oesophageal stenting, differences in current stent designs and behaviour, as well as the pressing need to refine and modify devices in order to meet the new challenges.